Abstract: Background: Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology in individuals without dementia, especially among cognitively unimpaired. Prescreening on AD risk factors may facilitate recruitment, but the efficiency will depend on how…
Another EPAD year has passed and we are proud to look back at a lot of successful deliveries and established relationships. We are pleased to present some of our key achievements of the past 12 months. February On 4 February, over 90 representatives of the EPAD project met in Berlin for an investigator meeting. The…
This month, we get to know the Aeginition Hospital (Athens, Greece) centre behind EPAD. The team of Nikolaos Scarmeas (principal investigator of the EPAD project in Aeginition Hospital) began recruiting in September 2019 and has currently recruited 14 participants in the EPAD Longitudinal Cohort Study (LCS). We caught up with his team and asked them…
We would like to share the internal release of the baseline data from the first 1500 research participants (V1500.0) for the EPAD Longitudinal Cohort Study. The data set is now available and accessible to all EPAD partners and Trial Delivery Centres for an embargoed period of 6 months. Following which access will be opened to…
This month, we get to know the Fundació ACE centre behind EPAD. The team of Dr. Mercè Boada (principal investigator of the EPAD project in Fundació ACE) began recruiting in June 2019 and has currently recruited over 60 participants in the EPAD Longitudinal Cohort Study (LCS). We caught up with her team and asked them…
EPAD is pleased to announce the release of a new publication entitled “The European Prevention of Alzheimer’s Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0” in the Journal of Prevention of Alzheimer’s disease. This paper describes the baseline data from the first 500 research participants (V500.0) to assist current and future researchers with their…
The European Prevention of Alzheimer’s Dementia (EPAD), a major Europe-wide initiative aiming to improve the understanding of the early stages of Alzheimer’s disease, has announced the release of its first wave of data as part of its EPAD Longitudinal Cohort Study. The project is one of the world leading dementia prevention studies involving 39 organisations.…
What is your current role in EPAD? I am a project manager for the overall EPAD project. My main role, as member of the EPAD Project Management office (WP5), is to provide overall management to the project including supporting the coordinator in liaising with the Innovative Medicines Initiative (IMI), follow up and management of the…
What is your current role in EPAD? I was the local EPAD Principal Investigator but my neurology colleague Tobias Langheinrich has recently taken over. Greater Manchester is one of the EPAD sites. The Greater Manchester Dementia Research Centre (GMDRC) is a collaboration between the NIHR, Greater Manchester Mental Health Foundation Trust and the University of…
As part of the Clinical Trials Digital Week, KNect365 Life Sciences organised a global 4-day series of live educational webcasts and downloadable resources providing the latest insights into clinical partnerships, outsourcing, operations and technology from 13-16 May 2019. Katrin Haeverans (Clinical Scientist and External Affairs Director at Janssen) was invited to deliver a webinar on…
